PRE-dialysis survey on anaemia management
- PMID: 12480965
- DOI: 10.1093/ndt/18.1.89
PRE-dialysis survey on anaemia management
Abstract
Background: The PRE-dialysis survey on anaemia management (PRESAM) was designed to assess the care given to pre-dialysis patients in the 12 months before haemodialysis or peritoneal dialysis, with emphasis on anaemia management.
Methods: For this epidemiological study, a retrospective chart review was conducted for patients who started haemodialysis or peritoneal dialysis between 1 August, 1999 and 6 April, 2000. All adult patients who entered one of the 779 participating centres in 21 European countries, Israel or South Africa were included, except for patients who underwent dialysis only during an acute episode. In addition to demographic characteristics, the study examined the prevalence of anaemia, anaemia management including the use of iron supplementation and epoetin, source of referral to the dialysis centre, comorbidities and major clinical events.
Results: A total of 4333 new dialysis patients were included in the survey. At the first visit to the dialysis centre, 68% of the patients had a haemoglobin (Hb) concentration < or = 11.0 g/dl; Hb concentration was positively correlated with creatinine clearance rate (r = 0.43, P < 0.01). Patients who received epoetin had a mean Hb concentration of 8.8 g/dl at the start of epoetin treatment, and 96% of these patients had an Hb concentration < or = 11.0 g/dl. Only 26.5% of the patients received epoetin before dialysis. The length of time under the care of a nephrologist was associated with meeting the European Best Practice Guidelines (EBPG) target Hb concentration, as well as receiving epoetin.
Conclusions: Few pre-dialysis patients met the EBPG target for Hb concentration, despite regular nephrology care.
Similar articles
-
Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.Nephrol Dial Transplant. 2005 May;20 Suppl 3:iii3-24. doi: 10.1093/ndt/gfh1074. Nephrol Dial Transplant. 2005. PMID: 15824128
-
Anaemia management in chronic kidney disease patients: an overview of current clinical practice.Nephrol Dial Transplant. 2002;17 Suppl 1:13-8. doi: 10.1093/ndt/17.suppl_1.13. Nephrol Dial Transplant. 2002. PMID: 11812907 Review.
-
Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients.Nephrol Dial Transplant. 2002 Sep;17(9):1621-7. doi: 10.1093/ndt/17.9.1621. Nephrol Dial Transplant. 2002. PMID: 12198213
-
[Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].Presse Med. 2003 Feb 8;32(5):212-6. Presse Med. 2003. PMID: 12610461 French.
-
[Guidelines for the treatment of anemia in chronic renal failure].G Ital Nefrol. 2003 Sep-Oct;20 Suppl 24:S61-82. G Ital Nefrol. 2003. PMID: 14666504 Review. Italian.
Cited by
-
Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study.World J Nephrol. 2016 Jul 6;5(4):358-66. doi: 10.5527/wjn.v5.i4.358. World J Nephrol. 2016. PMID: 27458564 Free PMC article.
-
Haemodialysis in an emerging centre in a developing country: a two year review and predictors of mortality.BMC Nephrol. 2011 Oct 2;12:50. doi: 10.1186/1471-2369-12-50. BMC Nephrol. 2011. PMID: 21962220 Free PMC article.
-
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23. Clin J Am Soc Nephrol. 2014. PMID: 24458078 Free PMC article. Clinical Trial.
-
A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.J Nephrol. 2024 May;37(4):1107-1119. doi: 10.1007/s40620-023-01849-9. Epub 2024 Jan 8. J Nephrol. 2024. PMID: 38189866 Review.
-
Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.Clin Drug Investig. 2012 Feb 1;32(2):99-110. doi: 10.2165/11594040-000000000-00000. Clin Drug Investig. 2012. PMID: 22117178 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous